What is a stock summary page? Click here for an overview.
Business Description
China SXT Pharmaceuticals Inc
ISIN : VGG2161P1403
Share Class Description:
SXTC: Ordinary SharesCompare
Compare
Traded in other countries / regions
SXTC.USA2RY.Germany Index Membership
China Concepts StockNASDAQ Golden Dragon China Index IPO Date
2019-01-04Description
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.56 | |||||
| Equity-to-Asset | 0.34 | |||||
| Debt-to-Equity | 0.26 | |||||
| Debt-to-EBITDA | 0.42 | |||||
| Interest Coverage | 15.89 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 0.81 | |||||
| Beneish M-Score | -2.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -75.4 | |||||
| 3-Year EBITDA Growth Rate | 63.9 | |||||
| 3-Year EPS without NRI Growth Rate | 66.6 | |||||
| 3-Year FCF Growth Rate | 63 | |||||
| 3-Year Book Growth Rate | -76.7 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.37 | |||||
| 9-Day RSI | 39.71 | |||||
| 14-Day RSI | 42.1 | |||||
| 3-1 Month Momentum % | 15.59 | |||||
| 6-1 Month Momentum % | -29.18 | |||||
| 12-1 Month Momentum % | -67.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Days Inventory | 156.18 | |||||
| Days Sales Outstanding | 265.75 | |||||
| Days Payable | 341.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -310.7 | |||||
| Shareholder Yield % | 2.28 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 22.06 | |||||
| Operating Margin % | 340.81 | |||||
| Net Margin % | 318.76 | |||||
| FCF Margin % | -148.79 | |||||
| ROE % | 59.56 | |||||
| ROA % | 25.68 | |||||
| ROIC % | 39.35 | |||||
| 3-Year ROIIC % | 51.81 | |||||
| ROC (Joel Greenblatt) % | 82.04 | |||||
| ROCE % | 37.41 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 0.12 | |||||
| PE Ratio without NRI | 0.12 | |||||
| PS Ratio | 0.32 | |||||
| PB Ratio | 0.13 | |||||
| Price-to-Tangible-Book | 0.13 | |||||
| EV-to-EBIT | 4.2 | |||||
| EV-to-EBITDA | 4.08 | |||||
| EV-to-Revenue | 14.27 | |||||
| EV-to-FCF | -9.59 | |||||
| Price-to-GF-Value | 0.31 | |||||
| Price-to-Projected-FCF | 0.03 | |||||
| Price-to-Graham-Number | 0.03 | |||||
| Price-to-Net-Current-Asset-Value | 1.11 | |||||
| Earnings Yield (Greenblatt) % | 23.81 | |||||
| FCF Yield % | -7.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SXTC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
China SXT Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.818 | ||
| EPS (TTM) ($) | 21.948 | ||
| Beta | 1.46 | ||
| 3-Year Sharpe Ratio | -1.23 | ||
| 3-Year Sortino Ratio | -1.47 | ||
| Volatility % | 95.47 | ||
| 14-Day RSI | 42.1 | ||
| 14-Day ATR ($) | 0.430546 | ||
| 20-Day SMA ($) | 3.10085 | ||
| 12-1 Month Momentum % | -67.41 | ||
| 52-Week Range ($) | 2.4 - 26.96 | ||
| Shares Outstanding (Mil) | 13.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
China SXT Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
China SXT Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
China SXT Pharmaceuticals Inc Frequently Asked Questions
What is China SXT Pharmaceuticals Inc(SXTC)'s stock price today?
The current price of SXTC is $2.57. The 52 week high of SXTC is $26.96 and 52 week low is $2.40.
When is next earnings date of China SXT Pharmaceuticals Inc(SXTC)?
The next earnings date of China SXT Pharmaceuticals Inc(SXTC) is 2025-04-04 Est..
Does China SXT Pharmaceuticals Inc(SXTC) pay dividends? If so, how much?
China SXT Pharmaceuticals Inc(SXTC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers